Isodiol International – CBD businesses growing around the globe
|Current Share Price||$1.50|
|52 Week High||$2.14|
|52 Week Low||$0.10|
|Shares Outstanding (MM)||301.7|
|Warrants Outstanding (MM)||84.8|
|Options Outstanding (MM)||17.9|
|Fully Diluted (MM)||386.5|
|Market Cap (MM)||$419.4|
Isodiol International (CSE:ISOL) Manufactures and develops raw ingredients and consumer products derived from hemp. They are pioneers of many forms of hemp derivatives (CBD) products including a +99% pure crystalline powder, capsules, edibles, topicals and extracts for use various food & beverage and pharmaceutical grade applications. They have had significant growth in their quarterly sales and generated over $5.8M last quarter alone.
They are the industry leader in the manufacturing and development of CBD (CannaBiDiol) consumer products and are focused on expanding their hemp derived portfolio and developing over-the-counter and pharmaceutical drugs while also aggressively pursuing international expansion into Latin America, Asia and Europe.
They have acquired several companies in the sector which have their own diverse product line and branding. Their proprietary purification processes are ISO 9001 certified and GMP certified and they have a very strong Intellectual Property portfolio with 20 pending trademarks and currently have over 100 SKU in production.
Their flagship product, ISO99™ Bioactive Anhydrous Hemp Oil is the first to market and still the purest, most bioactive hemp derivative in its class. They also have developed a crystalline formal that is 99+% pure compound can be added to foods, beverages, nutritional supplements, topicals, and even cosmetics. It is an Approved Pharmaceutical Ingredient (API) in select markets across the globe.
Some other key Brands and divisions
ISO-Sport – Hemp-based nutrition line catered towards professional athletes with the goal of assisting athletes with their training and recovery process and their daily lives. Recently announced sponsorship agreement with Cage Warriors (European UFC)
Pot-O-Coffee – Cannabis infused K-cups for tea and coffee, with different products containing THC and CBD. Has licensing relationships with Canopy Growth, where Canopy has the right to manufacture and distribute the company’s Pot-O-Coffee and Pot-O-Tea branded marijuana-infused single-serve K-Cup products in Canada.
Be Tru Organics – hemp extract products including topicals, oral sprays and edibles
CBDXtreme – CBD infused e-liquids, energy drinks and edibles
Bradley’s Brands – CBD e-liquids, gummies, merchandise, personal care products,
C3 Global Biosciences – CBD research, science, innovation and technology, Hemp CBD capsules, salves, sprays, and other topicals.
Canadian National Pharma Group – Pharmaceutical manufacturing company which is currently in the process of receiving its Licensed Dealer (“LD”) to commence production of cannabis and hemp extracts or isolates.
Iso-Bev – Manufacturing and development of raw ingredients and consumer beverages derived from hemp.
Biosynthesis Pharma Group – Producer of industrial hemp and industrial-sized extractor of proprietary high-purity CDB which is used in pharmaceutical applications. Operations in Hong Kong, Austria, China, UK and Brazil.
Aman Parmar – Chairman – Extensive experience in the capital markets involving corporate restructurings and financing for both private and public companies in the Manufacturing, Health Care, Real Estate and Resource sectors.
Marcos Agramont – CEO, COO & Director – Leading innovator in the Cannabis Industry for the last five years developing products for domestic and international channels. He has pioneered delivery systems, regulations and processes for major brands and helped introduce CBD to the global pharmaceutical market.
Troy Nihart – President– +20 years of business development and entrepreneurship experience and developed an international supply chain for the US Market of hemp derived CBD and has developed some of the most recognized brands in the cannabis industry.
Bryan Loree – CFO – 10 year veteran of numerous issuers on the TSX-V, CSE and private companies.
- Rapid revenue growth as they expand their presence in South America, Asia and Europe.
- Clinical trial outcomes on their flagship +99% crystalline isolate product.
- Fully cashed up with ~$42M in the bank to make strategic acquisitions.
Isodol has strong sales growth and are well positioned in the CBD market both in Canada and internationally. There are roughly 12 million shares from a $0.74 Private Placement that that will be free trading at the end of March, but if they keep their sales trajectory and maintain their growth strategy they should chew through the cheap paper and will be prime for a breakout with their upcoming news flow.
Fortune Favours the Bold
If you notice any errors with our articles, please send an email to email@example.com